All In Biotech

Drug Trial Radar · NCT06475274

A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery

A Phase 2b, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Dose-Finding Study to Evaluate the Efficacy on Renal Function and Safety of RMC-035 in Participants at High Risk for Kidney Injury Following Open-Chest Cardiac Surgery

Last checked: Nov 19, 2026Latest source record: Oct 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 170 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

170

Actual

Start

Aug 26, 2024

Primary completion

Sep 11, 2025

Study completion Sep 11, 2025

Sponsor

Lead sponsor
Guard Therapeutics ABIndustry
Sponsor type
Industry
First posted
Jun 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 84 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to identify the optimal dose of RMC-035 for protection of long-term renal function in adult patients undergoing cardiac surgery who are at high risk of kidney injury. It will also learn about the safety of RMC-035. The main question it aims to answer is: * Does RMC-035 protect the function of kidneys after surgery? * Is RMC-035 safe? Researchers will compare RMC-035 in high dose, RMC-035 in low dose and placebo to see if * Kidney function better for participants treated with any of the RMC-035 doses? * What medical problems do participants have when receiving RMC-035? Participants will * Receive 3 doses of RMC-035 or placebo: at the beginning of surgery, end of surgery and 24h after surgery * Have extra checkups and tests during their hospital stay * Visit the clinic at two extra occasions at 60 days and 90 days after surgery for checkups and tests

Conditions

  • Kidney Injury Following Open-Chest Cardiac Surgery

Interventions

  • RMC-035Drug

    Protein, a recombinant variant of A1M. Concentrate for solution for infusion.

  • PlaceboDrug

    Identical to RMC-035 intervention devoid of the active substance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in eGFR at Day 90 (the two arms of RMC-035 pooled compared against placebo)Time frame: 90 days

Locations

19 sites in 4 countries. Site status is shown where the registry gives one.

  • Research site 4

    Montreal, Canada

  • Research site 5

    Montreal, Canada

  • Research site 2

    Québec, Canada

  • Research site 3

    Saint John, Canada

  • Research site 1

    Toronto, Canada

  • Research site 1

    Hradec Králové, Czechia

  • Research site 2

    Prague, Czechia

  • Research site 5

    Dresden, Germany

  • Research site 3

    Essen, Germany

  • Research site 6

    Giessen, Germany

  • Research site 4

    Halle, Germany

  • Research site 2

    München, Germany

  • Research site 1

    Münster, Germany

  • Research site 3

    Barcelona, Spain

  • Research site 4

    Córdoba, Spain

  • Research site 1

    Madrid, Spain

  • Research site 2

    Madrid, Spain

  • Research site 6

    Pamplona, Spain

  • Research site 5

    Santiago de Compostela, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.